Clinical Scorecard: Solving the Problem of Insolubility: Part II
At a Glance
| Category | Detail |
|---|---|
| Condition | Insoluble drug molecules |
| Key Mechanisms | KinetiSol technology converts poorly soluble crystals into molecular form using mechanical energy and excipients as solvents. |
| Target Population | Patients requiring effective drug delivery of poorly soluble compounds. |
| Care Setting | Pharmaceutical manufacturing and drug formulation. |
Key Highlights
- KinetiSol addresses severe solubility challenges in drug formulation.
- The process generates amorphous dispersions efficiently without solvents.
- Dense, free-flowing particles improve drug solubility and prevent recrystallization.
Guideline-Based Recommendations
Diagnosis
- Identify molecules with poor solubility and high melting points.
Management
- Utilize KinetiSol for efficient manufacturing of amorphous drug delivery systems.
Monitoring & Follow-up
- Assess the solubility and dissolution properties of the final product.
Risks
- Consider risks associated with high melting temperatures and potential degradation during processing.
Patient & Prescribing Data
Patients with conditions requiring drugs that are poorly soluble.
KinetiSol enables the use of previously undruggable molecules by improving their solubility.
Clinical Best Practices
- Employ KinetiSol technology for the formulation of high melting point drugs.
- Conduct thorough testing of drug solubility post-manufacturing.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
